Results were dichotomized into negative and positive based on a cutoff of 10% ERCC1 antibody reactivity within tumor cells (i.e., a positive result indicated that at least 10% of cells demonstrated a reactivity to the ERCC1 antibody). The gene discussed is ERCC1; the disease is neoplasm.